Elaboration of a benzofuran scaffold and evaluation of binding affinity and inhibition of Escherichia coli DsbA: A fragment-based drug design approach to novel antivirulence compounds
Duncan, Luke F., Wang, Geqing, Ilyichova, Olga V., Dhouib, Rabeb, Totsika, Makrina, Scanlon, Martin J., Heras, Begoña, & Abbott, Belinda M. (2021) Elaboration of a benzofuran scaffold and evaluation of binding affinity and inhibition of Escherichia coli DsbA: A fragment-based drug design approach to novel antivirulence compounds. Bioorganic and Medicinal Chemistry, 45, Article number: 116315.
Description
Bacterial thiol-disulfide oxidoreductase DsbA is essential for bacterial virulence factor assembly and has been identified as a viable antivirulence target. Herein, we report a structure-based elaboration of a benzofuran hit that bound to the active site groove of Escherichia coli DsbA. Substituted phenyl groups were installed at the 5- and 6-position of the benzofuran using Suzuki-Miyaura coupling. HSQC NMR titration experiments showed dissociation constants of this series in the high µM to low mM range and X-ray crystallography produced three co-structures, showing binding in the hydrophobic groove, comparable with that of the previously reported benzofurans. The 6-(m-methoxy)phenyl analogue (2b), which showed a promising binding pose, was chosen for elaboration from the C-2 position. The 2,6-disubstituted analogues bound to the hydrophobic region of the binding groove and the C-2 groups extended into the more polar, previously un-probed, region of the binding groove. Biochemical analysis of the 2,6-disubsituted analogues showed they inhibited DsbA oxidation activity in vitro. The results indicate the potential to develop the elaborated benzofuran series into a novel class of antivirulence compounds.
Impact and interest:
Citation counts are sourced monthly from Scopus and Web of Science® citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.
| ID Code: | 212657 | ||
|---|---|---|---|
| Item Type: | Contribution to Journal (Journal Article) | ||
| Refereed: | Yes | ||
| ORCID iD: |
|
||
| Additional Information: | Funding Information: This research was supported by National Health and Medical Research Council (NHMRC) project (grants 1099151 and 1144046) and the Australian research council (Future Fellowship (FT130100580) and Discovery Project (DP190101613)). Dr Luke Duncan would like to acknowledge La Trobe University as a recipient of La Trobe University Postgraduate Research Scholarship. Dr Makrina Totsika would like to acknowledge support from Queensland University of Technology as a recipient of a Vice-Chancellor’s Research Fellowship. We would also like to acknowledge the La Trobe University-Comprehensive Proteomics Platform and the Monash Fragment Platform (MFP) for providing infrastructure and expertise. This research was undertaken on the MX1 and MX2 beamlines at the Australian Synchrotron, part of Australian Nuclear Science and Technology Organisation (ANSTO). We are very grateful for the ongoing support and many helpful chemical discussions provided by Dr Les Deady. | ||
| Measurements or Duration: | 13 pages | ||
| Additional URLs: | |||
| Keywords: | Antivirulence, Benzofuran, DsbA, Enzyme inhibition, Fragment-based drug discovery, Oxidoreductase | ||
| DOI: | 10.1016/j.bmc.2021.116315 | ||
| ISSN: | 0968-0896 | ||
| Pure ID: | 96886410 | ||
| Divisions: | Current > Research Centres > Centre for Immunology and Infection Control Current > QUT Faculties and Divisions > Faculty of Health Current > Schools > School of Biomedical Sciences |
||
| Funding Information: | This research was supported by National Health and Medical Research Council (NHMRC) project (grants 1099151 and 1144046) and the Australian research council (Future Fellowship (FT130100580) and Discovery Project (DP190101613)). Dr Luke Duncan would like to acknowledge La Trobe University as a recipient of La Trobe University Postgraduate Research Scholarship. Dr Makrina Totsika would like to acknowledge support from Queensland University of Technology as a recipient of a Vice-Chancellor’s Research Fellowship. We would also like to acknowledge the La Trobe University-Comprehensive Proteomics Platform and the Monash Fragment Platform (MFP) for providing infrastructure and expertise. This research was undertaken on the MX1 and MX2 beamlines at the Australian Synchrotron, part of Australian Nuclear Science and Technology Organisation (ANSTO). We are very grateful for the ongoing support and many helpful chemical discussions provided by Dr Les Deady. | ||
| Funding: | |||
| Copyright Owner: | Crown Copyright © 2021 Published by Elsevier Ltd. | ||
| Copyright Statement: | This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to qut.copyright@qut.edu.au | ||
| Deposited On: | 18 Aug 2021 15:35 | ||
| Last Modified: | 22 Apr 2026 15:41 |
Export: EndNote | Dublin Core | BibTeX
Repository Staff Only: item control page